Company intelligence / Profile preview

Opus Genomics

Durham, North Carolina, United States of Americapmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Employees: ~18
Development stage: Commercial

Overview

Opus Genetics has advanced multiple first-in-class retinal gene therapies into clinical development targeting ultra-orphan inherited retinal diseases. The pipeline includes several candidates addressing specific genetic causes of blindness, with ongoing clinical trials for some programs.

Therapeutic areas: Ophthalmology
Modalities: Gene therapy
Industry: Biotech

Beyond the preview

Go deeper on Opus Genomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Opus Genomics.

Explore the full profile